Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam
Background: For anti-infective agents, pharmacodynamics (PD) parameters have been proposed as predictors of clinical and microbiological success. Hospital-Acquired Pneumonia (HAP) patients have altered pharmacokinetics (PK) that needs to be considered when dosing antibiotics. We conducted a prospect...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84858971454&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/51981 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
id |
th-cmuir.6653943832-51981 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-519812018-09-04T06:13:26Z Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam Narawadeeniamhun Duangchit Panomvana Pintip Pongpech Athavudhdeesomchok Pharmacology, Toxicology and Pharmaceutics Background: For anti-infective agents, pharmacodynamics (PD) parameters have been proposed as predictors of clinical and microbiological success. Hospital-Acquired Pneumonia (HAP) patients have altered pharmacokinetics (PK) that needs to be considered when dosing antibiotics. We conducted a prospective study to assess (PK/PD) of cefoperazone/sulbactam treatment in HAP patients and to identify patient and PD indices associated with clinical response. Methods: Patients with HAP were identified, and information related to patient demographics, clinical status, antibiotic treatment and clinical outcome were documented. Cefoperazone/Sulbactam plasma concentrations were analyzed by validated High-Performance Liquid Chromatography (HPLC).Patient characteristics and PK/PD related factors were tested for associations with clinical outcome. Results: Twenty eight patients of hospital-acquired pneumonia patients were identified. 26 patients (93.1%) had Acinetobacterbaumannii infection and 2 patients (6.9%) had both of Pseudomonas aeruginosa and Acinetobacterbaumannii infection. At the end of treatment, clinical cure was note in 25 % of patients (7/28), improvement 46.4% (13/28) and 28.5% (8/28) had clinical failure. For microbiology outcome, microbiological eradication was note in 12 /28 (42.9%), 12/28 (42.9%) patients had organism persistence and 4 (14.3%) patients had new infection organism.The time which total cefoperazone concentration exceed the MIC (50% T>MIC) and age of the patient who was less than 60 years were significantly associated with clinical response (p<0.05) Conclusion: The percent of a dosing interval in which thecefoperazone serum concentration is above the MIC (%T>MIC) is strongly associated with clinical outcomeand is essential to the appropriate management of A.baumanii and P.aeruginosa infections. 2018-09-04T06:13:26Z 2018-09-04T06:13:26Z 2012-03-30 Journal 09751491 2-s2.0-84858971454 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84858971454&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/51981 |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
country |
Thailand |
collection |
CMU Intellectual Repository |
topic |
Pharmacology, Toxicology and Pharmaceutics |
spellingShingle |
Pharmacology, Toxicology and Pharmaceutics Narawadeeniamhun Duangchit Panomvana Pintip Pongpech Athavudhdeesomchok Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam |
description |
Background: For anti-infective agents, pharmacodynamics (PD) parameters have been proposed as predictors of clinical and microbiological success. Hospital-Acquired Pneumonia (HAP) patients have altered pharmacokinetics (PK) that needs to be considered when dosing antibiotics. We conducted a prospective study to assess (PK/PD) of cefoperazone/sulbactam treatment in HAP patients and to identify patient and PD indices associated with clinical response. Methods: Patients with HAP were identified, and information related to patient demographics, clinical status, antibiotic treatment and clinical outcome were documented. Cefoperazone/Sulbactam plasma concentrations were analyzed by validated High-Performance Liquid Chromatography (HPLC).Patient characteristics and PK/PD related factors were tested for associations with clinical outcome. Results: Twenty eight patients of hospital-acquired pneumonia patients were identified. 26 patients (93.1%) had Acinetobacterbaumannii infection and 2 patients (6.9%) had both of Pseudomonas aeruginosa and Acinetobacterbaumannii infection. At the end of treatment, clinical cure was note in 25 % of patients (7/28), improvement 46.4% (13/28) and 28.5% (8/28) had clinical failure. For microbiology outcome, microbiological eradication was note in 12 /28 (42.9%), 12/28 (42.9%) patients had organism persistence and 4 (14.3%) patients had new infection organism.The time which total cefoperazone concentration exceed the MIC (50% T>MIC) and age of the patient who was less than 60 years were significantly associated with clinical response (p<0.05) Conclusion: The percent of a dosing interval in which thecefoperazone serum concentration is above the MIC (%T>MIC) is strongly associated with clinical outcomeand is essential to the appropriate management of A.baumanii and P.aeruginosa infections. |
format |
Journal |
author |
Narawadeeniamhun Duangchit Panomvana Pintip Pongpech Athavudhdeesomchok |
author_facet |
Narawadeeniamhun Duangchit Panomvana Pintip Pongpech Athavudhdeesomchok |
author_sort |
Narawadeeniamhun |
title |
Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam |
title_short |
Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam |
title_full |
Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam |
title_fullStr |
Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam |
title_full_unstemmed |
Pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam |
title_sort |
pharmacodynamic target associated with clinical outcome of hospital-acquired pneumonia treatment with cefoperazone/sulbactam |
publishDate |
2018 |
url |
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84858971454&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/51981 |
_version_ |
1681423867910815744 |